AAN 2021 | The expanding treatment landscape for myasthenia gravis

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, gives an overview of the current treatment landscape for myasthenia gravis as well as upcoming advances in the field. Prof. Howard highlights that the broad-spectrum immunosuppressants currently used are associated with several adverse events. Although improvements have been made in the disease burden, the treatment burden faced by myasthenia gravis patients is substantial and not acceptable to many. The future is gratifying with new targeted therapies, such as complement inhibitors and FcRn inhibitors, that will help reduce the treatment burden in terms of adverse events. Other advances on the horizon include CD19 and CD38 inhibition as well as CAR-T therapy. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.